Comparison of gatifloxacin, moxifloxacin and ciprofloxacin for treatment of experimental Burkholderia pseudomallei infection

Journal of Antimicrobial Chemotherapy

Volumn 55, Issue 4, 2005, Pages 523-527

  Steward, J ^a   Piercy, T ^a   Lever, M S ^a   Nelson, M ^a   Simpson, A J H ^a,b   Brooks, T J S ^a,c  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c HPA Porton Down   (United Kingdom)

Author keywords

Chemotherapy; Fluoroquinolones; Melioidosis; Murine

Indexed keywords

CIPROFLOXACIN; DEXAMETHASONE; GATIFLOXACIN; MOXIFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL INFECTION; BURKHOLDERIA PSEUDOMALLEI; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL INFECTION; FEMALE; MOUSE; MOUSE STRAIN; NONHUMAN; PERSISTENT INFECTION; RECURRENCE RISK; SUBCUTANEOUS TISSUE; SURVIVAL RATE;

ANIMALS; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CIPROFLOXACIN; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROQUINOLONES; GLUCOCORTICOIDS; MELIOIDOSIS; MICE; MICE, INBRED BALB C; QUINOLINES;

EID: 17444402523     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki039     Document Type: Article

References (34)

1. Dance, D. A. B. (1991). Melioidosis: the tip of the iceberg? Clinical Microbiology Reviews 4, 52-60.
2. Koponen, M. A., Zlock, D., Palmer, D. L. et al. (1991). Melioidosis: forgotten, but not gone. Archives of Internal Medicine 137, 605-8.
3. Chaowagul, W., Suputtamongkul, Y., Dance, D. A. B. et al. (1993). Relapse in melioidosis: incidence and risk factors. Journal of Infectious Diseases 168, 1181-5.
4. Ip, M., Osterberg, L. G., Chau, P. Y. et al. (1995). Pulmonary melioidosis. Chest 108, 1420-4.
5. Rajchanuvong, A., Chaowagul, W., Suputtamongkol, Y. et al. (1995). A prospective comparison of co-amoxiclav and the combination of chloramphenicol, doxycycline and co-trimoxazole for the oral maintenance treatment of melioidosis. Transactions of the Royal Society of Tropical Medicine and Hygiene 89, 546-9.
6. Simpson, A. J. H., Suputtamongkol, Y., Smith, M. D. et al. (1999). Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clinical Infectious Diseases 29, 381-7.
7. Chetchotisakd, P., Chaowagul, W., Mootsikapun, P. et al. (2001). Maintenance therapy of melioidosis with ciprofloxacin plus azithromycin compared with co-trimoxazole plus doxycycline. American Journal of Tropical Medicine and Hygiene 64, 24-7.
8. Russell, P., Eley, S. M., Ellis, J. et al. (2000). Comparison of efficacy of ciprofloxacin and doxycycline against experimental melioidosis and glanders. Journal of Antimicrobial Chemotherapy 45, 813-8.
9. White, N. J. (2003). Melioidosis. Lancet 361, 1715-22.
10. Cheng, A. C., Fisher, D. A., Anstey, N. M. et al. (2004). Outcomes of patients with melioidosis treated with meropenem. Antimicrobial Agents and Chemotherapy 48, 1763-5.
11. Dance, D. A. B. (2002). Melioidosis. Current Opinion in Infectious Diseases 15, 127-32.
12. Chaowagul, W. (2000). Recent advances in the treatment of severe melioidosis. Acta Tropica 74, 133-7.
13. Health Protection Agency. (2003). Health Protection Agency Interim Guidelines for Action in the Event of a Deliberate Release: Glanders & Melioidosis, version 2.2, 14 August 2003. HPA, London. [Online.] http://www.hpa.org.uk/infections/topics_az/deliberate_release/menu.htm (6 April 2004, date last accessed).
14. Chaowagul, W., Suputtamongkul, Y., Smith, M. D. et al. (1997). Oral fluoroquinolones for maintenance treatment of melioidosis. Transactions of the Royal Society of Tropical Medicine and Hygiene 91, 599-601.
15. Ashdown, L. R. & Currie, B. J. (1992). Melioidosis: when in doubt leave the quinolone alone! Medical Journal of Australia 157, 427-8.
16. Steward, J., Lever, M. S., Simpson, A. J. H. et al. (2004). Post-exposure prophylaxis and treatment of systemic anthrax in mice with fluoroquinolones. Journal of Antimicrobial Chemotherapy 54, 95-9.
17. National Committee for Clinical Laboratory Standards. (1993). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Third Edition: Approved Standard M7-A3. NCCLS, Villanova, PA, USA.
18. Dance, D. A. B., Wuthiekanun, V., Chaowagul, W. I. et al. (1989). The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in-vitro and during treatment. Journal of Antimicrobial Chemotherapy 24, 295-309.
19. Leelarasamee, A. & Bovornkitti, S. (1989). Melioidosis: review and update. Reviews of Infectious Diseases 11, 413-25.
20. Ashdown, L. R. (1988). In-vitro activities of the newer β-lactam and quinolone agents against Pseudomonas pseudomallei. Antimicrobial Agents and Chemotherapy 32, 1435-6.
21. Centers for Disease Control and Prevention. (2004). Laboratory exposure to Burkholderia pseudomallei - Los Angeles, CA, 2003. Morbidity and Mortality Weekly Report 53, 988-90.
22. Currie, B. J., Fisher, D. A., Howard, D. M. et al. (2000). Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. Clinical Infectious Diseases 31, 981-6.
23. Chaowagul, W., Simpson, A. J. H., Suputtamongkol, Y. et al. (1999). A comparison of chloramphenicol, trimethoprim-sulfamethoxazole, and doxycycline with doxycycline alone as maintenance therapy for melioidosis. Clinical Infectious Diseases 29, 375-80.
24. Winton, M. D., Everett, E. D. & Dolan, S. A. (1988). Activities of five new fluoroquinolones against Pseudomonas pseudomallei. Antimicrobial Agents and Chemotherapy 32, 928-9.
25. Chau, P. Y., Ng, W. S., Leung, Y. K. et al. (1986). In vitro susceptibility of strains of Pseudomonas pseudomallei isolated in Thailand and Hong Kong to some newer β-lactam antibiotics and quinolone derivatives. Journal of Infectious Diseases 153 167-70.
26. Ho, P. L., Cheung, T. K. M., Kinoshita, R. et al. (2002). Activity of five fluoroquinolones against 71 isolates of Burkholderia pseudomallei. Journal of Antimicrobial Chemotherapy 49 1039-46.
27. Leakey, A. K., Ulett, G. C. & Hirst, R. G. (1998). BALB/c and C57BI/6 mice infected with virulent Burkholderia pseudomallei provide contrasting animal models for the acute and chronic forms of human melioidosis. Microbial Pathogenesis 24, 269-75.
28. Ulett, G. C., Norton, R. E. & Hirst, R. G. (1999). Combination antimicrobial therapy of acute Burkholderia pseudomallei infection in a mouse model. Pathology 31, 264-7.
29. Hoppe, I., Brenneke, B., Rohde, M. et al. (1999). Characterization of a murine model of melioidosis: comparison of different strains of mice. Infection and Immunity 67, 2891-900.
30. Morris, T. H. (1995). Antibiotic therapeutics in laboratory animals. Laboratory Animals 29, 16-36.
31. Bristol-Myers Squibb. (2000). Gatifloxacin package insert. Bristol-Myers Squibb, Princeton, NJ, USA.
32. Miyazaki, E., Miyazaki, M., Chen, J. M. et al. (1999). Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrobial Agents and Chemotherapy 43 85-9.
33. Ji, B., Lounis, N., Maslo, C. et al. (1998). In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 42, 2066-9.
34. Lumbiganon, P. & Sookpranee, T. (1992). Ciprofloxacin therapy for localized melioidosis. Pediatric Infectious Disease Journal 11, 418-9.